These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
117 related articles for article (PubMed ID: 7574268)
41. Extrapyramidal dopamine regulation by cholecystokinin and its role in Parkinson's disease. Diamond BI; Pasinetti G; Hitri A; Borison RL Adv Neurol; 1984; 40():483-8. PubMed ID: 6695625 [No Abstract] [Full Text] [Related]
42. Effect of phenothiazines on dopamine metabolism and biochemistry of Parkinson's disease. Barbeau A Agressologie; 1968; 9(2):195-200. PubMed ID: 5675486 [No Abstract] [Full Text] [Related]
43. The probenecid test. Korczyn AD J Neural Transm Suppl; 1983; 19():173-83. PubMed ID: 6142088 [TBL] [Abstract][Full Text] [Related]
45. [Dopaminergic neurons and clinical neuropsychiatry]. Ferrari E Acta Neurol (Napoli); 1992; 14(4-6):241-64. PubMed ID: 1293968 [TBL] [Abstract][Full Text] [Related]
46. [Biochemistry of neuronal transmission. Pharmacology of parkinsonism]. Lombardo L Gac Med Mex; 1981 Dec; 117(12):476-8. PubMed ID: 6123462 [No Abstract] [Full Text] [Related]
47. Parkinson's disease as a result of aging. Rodriguez M; Rodriguez-Sabate C; Morales I; Sanchez A; Sabate M Aging Cell; 2015 Jun; 14(3):293-308. PubMed ID: 25677794 [TBL] [Abstract][Full Text] [Related]
48. Restoration and targeting of aberrant neurotransmitters in Parkinson's disease therapeutics. Yadav D; Kumar P Neurochem Int; 2022 Jun; 156():105327. PubMed ID: 35331828 [TBL] [Abstract][Full Text] [Related]
50. Developments in the pharmacology and therapeutics of parkinsonism. Calne DB Ann Neurol; 1977 Feb; 1(2):111-9. PubMed ID: 18978 [No Abstract] [Full Text] [Related]
52. Effects of foods and nutrients on brain neurotransmitters. Wurtman RJ Curr Concepts Nutr; 1984; 13():103-12. PubMed ID: 6150811 [No Abstract] [Full Text] [Related]
53. Comment on the commonality of manganese neurotoxicity and Parkinson's disease. Graham DG Neurotoxicology; 1981 Oct; 2(2):387-8. PubMed ID: 7198760 [No Abstract] [Full Text] [Related]
54. [Changes in brain level of neurotransmitters]. Kanazawa I Nihon Naika Gakkai Zasshi; 1991 Jul; 80(7):1148-52. PubMed ID: 1680945 [No Abstract] [Full Text] [Related]
55. Biochemistry of the hypothalamus in Parkinson's disease. Javoy-Agid F; Ruberg M; Pique L; Bertagna X; Taquet H; Studler JM; Cesselin F; Epelbaum J; Agid Y Neurology; 1984 May; 34(5):672-5. PubMed ID: 6143285 [TBL] [Abstract][Full Text] [Related]
56. The chemical tools for imaging dopamine release. Post MR; Sulzer D Cell Chem Biol; 2021 Jun; 28(6):748-764. PubMed ID: 33894160 [TBL] [Abstract][Full Text] [Related]
57. Heterogeneity of dopamine release sites in health and degeneration. Lebowitz JJ; Khoshbouei H Neurobiol Dis; 2020 Feb; 134():104633. PubMed ID: 31698055 [TBL] [Abstract][Full Text] [Related]
58. Preclinical detection in studies of the etiology, natural history, and treatment of Parkinson's disease. Ellenberg JH Neurology; 1991 May; 41(5 Suppl 2):14-20. PubMed ID: 2041590 [TBL] [Abstract][Full Text] [Related]
59. The locus coeruleus: Another vulnerability target in Parkinson's disease. Oertel WH; Henrich MT; Janzen A; Geibl FF Mov Disord; 2019 Oct; 34(10):1423-1429. PubMed ID: 31291485 [No Abstract] [Full Text] [Related]
60. Parkinson's Disease: The Life Cycle of the Dopamine Neuron. September 18-20, 2002. Princeton, New Jersey, USA. Proceedings. Ann N Y Acad Sci; 2003 Jun; 991():1-360. PubMed ID: 12846968 [No Abstract] [Full Text] [Related] [Previous] [Next] [New Search]